BioMelbourne Network
Progressing BioIndustry
Latest News
Biota awarded $US231 million for phase III anti-influenza drug
6 April 2011
The Office of Biomedical Advanced Research and Development Authority (BARDA) within the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the US Department of Health and Human Services has awarded Biota up to $US231 million ($A223.7 million) over five years to its wholly owned subsidiary, Biota Scientific Management, for the advanced development of laninamivir.
The contract is designed to provide US based manufacturing and clinical data to support
a New Drug Application for laninamivir, to the US Food and Drug Administration.
Biota CEO, Peter Cook, commented, “The award provides visible recognition of the potential medical value of laninamivir to the world’s major market. The BARDA contract will be a major contributor to a timely introduction of the product and will create the
opportunity to significantly develop Biota’s business in the USA”. Read more
